ScripSanofi’s multiple sclerosis candidate tolebrutinib is in line for a potential US approval in the autumn after the Food and Drug Administration agreed to a speedy review of the oral Bruton’s tyrosine k
ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
ScripThe ultra-rare disease specialist Ultragenyx is approaching several important catalysts this year, including US Food and Drug Administration action on UX111 – the firm’s first gene therapy, which targ
ScripThe latest label expansion for Novartis’s Fabhalta (iptacopan), for C3 glomerulopathy (C3G), allows the firm to expand its growing presence in the renal disease space, which the Swiss drug maker will